Malignancy Rates in Brodalumab Clinical Studies for Psoriasis.

ABSTRACT:

Background

Brodalumab is a fully human anti-interleukin-17 receptor A monoclonal antibody efficacious for the treatment of adults with moderate-to-severe plaque psoriasis.

Objective

This study summarizes malignancy rates in psoriasis clinical studies of brodalumab.

Methods

Data were pooled from one phase II study and three large, multicenter, phase III randomized studies of brodalumab for the treatment of psoriasis, including two studies with randomization to brodalumab, ustekinumab, or placebo. Data from the 52-week (brodalumab and ustekinumab) and long-term (brodalumab) pools were summarized as exposure-adjusted or follow-up time-adjusted event rates per 100 patient-years (PY).

Results

Exposure-adjusted event rates per 100 PY at 52 weeks were lower with broda

SUBMITTER: Gottlieb A 

PROVIDER: S-EPMC7275023 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature